ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

CLDX Celldex Therapeutics Inc

39.35
1.93 (5.16%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Celldex Therapeutics Inc NASDAQ:CLDX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.93 5.16% 39.35 37.04 41.26 40.88 37.45 37.49 890,615 23:37:52

Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference

06/06/2017 9:01pm

GlobeNewswire Inc.


Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Celldex Therapeutics Charts.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Tibor Keler, Ph.D., Co-founder, Executive Vice President and Chief Scientific Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in a fireside chat at the Jefferies 2017 Global Healthcare Conference on June 8, 2017 at 11:00 a.m. EDT in New York.

The live webcast will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for seven days following the event.

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit www.celldex.com.

Company Contact

Sarah Cavanaugh
Vice President of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com

Charles Liles 
Associate Director of Investor Relations & Corp Communications 
Celldex Therapeutics, Inc. 
(781) 433-3107 
cliles@celldex.com

1 Year Celldex Therapeutics Chart

1 Year Celldex Therapeutics Chart

1 Month Celldex Therapeutics Chart

1 Month Celldex Therapeutics Chart

Your Recent History

Delayed Upgrade Clock